Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| X4 Pharmaceuticals, IncXFOR · Entity 5638 | Chief Legal Officer | May 20, 2025 | July 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
X4 Pharmaceuticals, Inc
Report date May 20, 2025 · Filed July 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,462 |
Reported balance
After 2025-05-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-05-20 · Grant · Acquired 3,333 · Balance 9,462 F1: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on May 10, 2026, May 10, 2027 and May 10, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date. F2: The reported amount has been adjusted to reflect a correction to the number of shares beneficially owned by the Reporting Person, which was inadvertently overstated by 855 shares on the Form 3 filed on June 3, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on May 10, 2026, May 10, 2027 and May 10, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date.
F2: The reported amount has been adjusted to reflect a correction to the number of shares beneficially owned by the Reporting Person, which was inadvertently overstated by 855 shares on the Form 3 filed on June 3, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2025 Filed Jul 3, 2025 16:21 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 3,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-034233 · wk-form4_1751574063.xml · nonDerivative · entry 1 Thoren Natasha Fay · CIK 0002070977 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,462 F1 · shares: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on May 10, 2026, May 10, 2027 and May 10, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date. F2 · balance_after: The reported amount has been adjusted to reflect a correction to the number of shares beneficially owned by the Reporting Person, which was inadvertently overstated by 855 shares on the Form 3 filed on June 3, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.